Zai Lab

Zai Lab Goodwill/Assets

Goodwill to Total Assets Ratio of Zai Lab (ZLAB) as of Oct 30, 2026.

Goodwill/Assets

-0.00

Last updated:

Goodwill to Total Assets Ratio of Zai Lab is 2023 -0.00 . Goodwill to Total Assets Ratio of Zai Lab was 2022 - . It decreases by % lower compared to the previous year.

The Zai Lab Goodwill/Assets history

The Zai Lab Goodwill/Assets history
YEARGoodwill/AssetsYoY
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Zai Lab since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Zai Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zai Lab

All Key Metrics — Zai Lab